Pharmaceutical

Delix plans further trials with neuroplastogen after positive Phase I data

The company will initiate Phase Ib and Phase II studies in major depression in 2024 and 2025, respectively.

Jul 16, 2024 - 04:00
Delix plans further trials with neuroplastogen after positive Phase I data
The company will initiate Phase Ib and Phase II studies in major depression in 2024 and 2025, respectively.
Read the original article

Tags:

Previous Article

¬AI model harnesses physics to autocorrect remote sensing data

Next Article

AbbVie looks to add an eighth indication for JAK inhibitor Rinvoq

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Fresenius Kabi and Cellular Origins agree CGT manufacture automation

Fresenius Kabi and Cellular Origins agree CGT manufactu...

Oct 18, 2024

STAT+: What to know about a pivotal FDA hearing on Sarepta’s gene therapy for Duchenne

STAT+: What to know about a pivotal FDA hearing on Sare...

May 9, 2023

STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest

STAT+: Here are the cancer drugs Pfizer thinks could re...

Feb 29, 2024